What strategies—communication about treatment expectations, managing side effects, use of bronchodilators, etc.—do you employ at the front lines of patient management when using amikacin liposome inhalation suspension in MAC lung disease?

What strategies—communication about treatment expectations, managing side effects, use of bronchodilators, etc.—do you employ at the front lines of patient management when using amikacin liposome inhalation suspension in MAC lung disease?

What strategies—communication about treatment expectations, managing side effects, use of bronchodilators, and others—do you employ at the front lines of patient management when using amikacin liposome inhalation suspension in MAC lung disease


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Mehdi Mirsaeidi, MD, MPH

Mehdi Mirsaeidi, MD, MPH

Director of University of Miami and VA Sarcoidosis Programs Co-Director UM NTM Program IRB Vice-Chairman, Miami VA Healthcare System Assistant Professor of Department of Medicine Assistant Professor of Clinical Public Health Sciences Division of Pulmonary